ENANTA PHARMACEUTICALS, INC
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M | $122.5M | $205.2M | $206.6M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $106.7M | $131.5M | $163.5M | $164.5M | $174.1M | $136.8M | $142.2M | $94.9M |
| SG&A Expense | $43.9M | $57.9M | $52.9M | $45.5M | $32.5M | $27.4M | $26.2M | $23.4M |
| Operating Income | $-85.3M | $-121.7M | $-137.2M | $-123.8M | $-109.6M | $-41.6M | $36.7M | $88.3M |
| Operating Margin | -130.7% | -179.9% | -173.2% | -143.7% | -112.9% | -34.0% | 17.9% | 42.7% |
| Interest Expense | — | — | $5.1M | $0 | $0 | — | — | — |
| Pretax Income | $-83.5M | $-117.8M | $-131.0M | $-122.2M | $-107.6M | $-35.0M | $45.6M | $93.1M |
| Income Tax Expense | $-1.7M | $-1.7M | $2.8M | $-433.0K | $-28.6M | $1.1M | $-826.0K | $21.2M |
| Net Income | $-81.9M | $-116.0M | $-133.8M | $-121.8M | $-79.0M | $-36.2M | $46.4M | $72.0M |
| Net Margin | -125.4% | -171.6% | -169.0% | -141.3% | -81.4% | -29.5% | 22.6% | 34.8% |
| EPS (Basic) | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 | $-1.81 | $2.37 | $3.74 |
| EPS (Diluted) | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 | $-1.81 | $2.21 | $3.48 |
| Shares Outstanding (Basic) | 21.3K | 21.2K | 21.0K | 20.6K | 20.2M | 19.9M | 19.6M | 19.3M |
| Shares Outstanding (Diluted) | 21.3K | 21.2K | 21.0K | 20.6K | 20.2M | 19.9M | 21.0M | 20.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |